Clinical trials: fludarabine phosphate, open to volunteers
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
GATA2, Immunodeficiency
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Background: GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition.
- Conditions
- GATA2, Immunodeficiency, MDS
- Trial name
- NCT01861106
- Testing
- Allogeneic HSCT, Busulfan Test dose, Fludarabine (Fludara, Berlex Laboratories)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
CD34+ Transplants for Myeloid Malignancies
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy…
- Trial name
- NCT05565105
- Testing
- Busulfan, Melphalan, Fludarabine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Guenther Koehne
Myelodysplastic Syndromes, Graft Vs Host Disease
CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat myelodysplastic syndrome…
- Conditions
- Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease
- Trial name
- NCT05617625
- Testing
- Busulfan, Melphalan, Fludarabine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Guenther Koehne
Myeloid Leukemia
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML.
- Trial name
- NCT07604233
- Testing
- Fludarabine, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells.
- Conditions
- Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma
- Trial name
- NCT06026319
- Testing
- CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Clear Cell Renal Cell Carcinoma
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC.
- Trial name
- NCT07564232
- Testing
- Cyclophosphamide, Fludarabine, LNK001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer, Metastatic
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of…
- Trial name
- NCT07509008
- Testing
- TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
This phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia or high-risk myelodysplastic…
- Conditions
- Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT07582172
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid…
- Conditions
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome
- Trial name
- NCT00801489
- Testing
- Cytarabine, Decitabine, Filgrastim-sndz
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
- Trial name
- NCT06066424
- Testing
- Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Autoimmune Disorders, Systemic Sclerosis
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and…
- Conditions
- Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus
- Trial name
- NCT06434363
- Testing
- Tafasitamab, Fludarabine phosphate, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Emapalumab Prevention of CAR-T Cell Associated Toxicities
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).
- Conditions
- Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06550141
- Testing
- Emapalumab, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Relapsed/Refractory Myeloma
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
- Trial name
- NCT06066359
- Testing
- Fludarabine phosphate, Cyclophosphamide, Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Peritoneal Metastases
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
- Conditions
- Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
- Trial name
- NCT07411599
- Testing
- Cyclophosphamide, Fludarabine, Cetuximab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Large B-cell Lymphoma
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have…
- Trial name
- ALPHA3 (NCT06500273)
- Testing
- cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide
- Where
- 85 sites in United States, Australia and 2 more
- Volunteers
- 250 people
- Sponsor
- Allogene Therapeutics
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of genetically engineered cells (CD83 chimeric antigen receptor [CAR] T cells) in treating patients with acute myeloid leukemia (AML) that has come back after a…
- Trial name
- NCT06871410
- Testing
- Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT05955261
- Testing
- Venetoclax, Azacitidine, Cytarabine
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- St. Jude Children's Research Hospital
Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders
This phase II clinical trial studies how well treosulfan, thiotepa, fludarabine, and rabbit anti-thymocyte globulin (rATG) before donor stem cell transplantation works in treating patients with nonmalignant (non-cancerous)…
- Trial name
- NCT03980769
- Testing
- Thiotepa, Treosulfan, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung…
- Conditions
- Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
- Trial name
- NCT05681780
- Testing
- Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute